16:10 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional area...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other molecule...
23:20 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Chimeric antigens against N. meningitidis fHbp and N. meningitidis porA could be used to develop vaccines against serogroup B N. meningitidis infection. The antigens were generated by using a soluble N. meningitidis fHbp...
20:59 , Oct 20, 2017 |  BioCentury  |  Finance

Stars align for rare AMD

Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use the precision medicine approach that is common to cancer and rare diseases to target mutations in the...
18:04 , Sep 1, 2017 |  BC Week In Review  |  Company News

Duke spinout Grid gets IP for CFH antibodies

Duke University (Durham, N.C.) granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke...
21:31 , Aug 22, 2017 |  BC Extra  |  Company News

Duke spinout Grid gets IP for CFH antibodies

Duke University granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke received a...
16:46 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

EC approves Pfizer's Trumenba

In May, the European Commission approved Trumenba meningococcal group B vaccine (recombinant LP2086, PF-5212366) from Pfizer Inc. (NYSE:PFE) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages ≥10. The vaccine...
05:19 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Trumenba regulatory update

EMA's CHMP recommended approval of an MAA from Pfizer for Trumenba meningococcal group B vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages ≥10. In 2014, FDA granted accelerated...
21:32 , Mar 24, 2017 |  BC Extra  |  Company News

CHMP backs Orphan candidates, PD-1 mAbs

On Friday, EMA's CHMP recommended approval of several candidates, including Orphan disease therapies Isqette dinutuximab beta (APN311) from Apeiron Biologics AG (Vienna, Austria) and Refixia nonacog beta pegol from Novo Nordisk A/S (CSE:NVO; NYSE:NVO). It...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Trumenba regulatory update

EMA accepted for review an MAA from Pfizer for Trumenba to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in individuals ages >=10. In 2014, FDA granted accelerated approval of the bivalent meningococcal...